Sven Rohmann
Vorsitzender bei Inprother ApS
Profil
Sven Rohmann is currently the Chairman at Hervolution ApS.
He also holds the position of Chief Business Development Officer at the Center for Molecular Medicine (Sweden) and Tcer AB.
Previously, he served as the Chief Executive Officer at Ganymed Pharmaceuticals AG, Biovision AG, and Mendus AB.
He was also the Chief Executive Officer & Director at Vivesto AB.
Dr. Rohmann has held various other positions such as Chairman at Helix BioPharma Corp., ImVisioN GmbH, and Helix Polska Sp zoo.
He was also the Director & Co-Chief Medical Officer-Global at LifeMD, Inc. Additionally, he has worked as the General Manager-Europe Region at Burrill LLC, General Partner at Nextech Invest AG, Vice President at ArcticZymes Technologies ASA, Chief Business Officer at Pantec Biosolutions AG, and Fund Manager at Novartis Pharma AG.
Dr. Rohmann holds a doctorate from Erasmus University Rotterdam and The Johannes Gutenberg University of Mainz.
He also has an MBA from Kellogg School of Management.
Aktive Positionen von Sven Rohmann
| Unternehmen | Position | Beginn |
|---|---|---|
| Center for Molecular Medicine (Sweden) | Corporate Officer/Principal | - |
| Tcer AB | Corporate Officer/Principal | - |
Inprother ApS
 Inprother ApS BiotechnologyHealth Technology Inprother ApS is a biotechnology company based in Copenhagen, Denmark. The Danish company aims to develop novel immunotherapies that target the human endogenous retroviruses (HERVs) as tumor-specific antigens. The company is funded by the Novo Nordisk Bioinnovation Institute and by grants from the Danish Innovation Fund and Eurostars. Inprother has put in place a world-class scientific team and created an emerging product development pipeline, including a leading program targeted to enter clinics in 2024. Inprother's approach is based on the research of founder and CTO, Dr. Peter Holst, and CTO, Dr. Anne-Marie Andersson. The company was founded in 2011 by Peter Johannes Holst. Jordi Naval has been the CEO of the company since 2021. | Vorsitzender | 24.05.2023 |
Ehemalige bekannte Positionen von Sven Rohmann
| Unternehmen | Position | Ende |
|---|---|---|
| MENDUS AB | Vorstandsvorsitzender | 16.03.2021 |
| HELIX BIOPHARMA CORP. | Vorstandsvorsitzender | 31.03.2017 |
ImVisioN GmbH
 ImVisioN GmbH Miscellaneous Commercial ServicesCommercial Services ImVisioN GmbH provides research in intralymphatic immunotherapy. It is a biotechnology company which specializes the use of intralymphatic immunotherapy to develop treatments for major allergies. Its product, IVN201, is a MAT immunotherapeutic that targets cat dander allergy, a common allergy inadequately addressed by available therapeutic interventions. The company was founded in 2005 and is headquartered in Hanover, Germany. | Vorsitzender | - |
| Biovision AG | Vorstandsvorsitzender | - |
| ARCTICZYMES TECHNOLOGIES ASA | Corporate Officer/Principal | - |
Ausbildung von Sven Rohmann
| Erasmus University Rotterdam | Doctorate Degree |
| The Johannes Gutenberg University of Mainz | Doctorate Degree |
| Kellogg School of Management | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 6 |
|---|---|
| HELIX BIOPHARMA CORP. | Health Technology |
| LIFEMD, INC. | Health Services |
| ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
| VIVESTO AB | Health Technology |
| MENDUS AB | Health Technology |
| ADIUVO INVESTMENTS S.A. | Health Technology |
| Private Unternehmen | 11 |
|---|---|
Burrill LLC
 Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | Finance |
Nextech Invest AG
 Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Finance |
Ganymed Pharmaceuticals AG
 Ganymed Pharmaceuticals AG BiotechnologyHealth Technology Ganymed Pharmaceuticals AG develops antibodies for the treatment of solid cancers. It focuses on developing ideal monoclonal antibodies that include cancer-selective targets for maximal high-precision anticancer potency, as well as mitigates the threat of toxicity. The company was founded by Özlem Türeci, Dirk L. Sebastian, Christoph Huber and Ugur Sahin in 2001 and is headquartered in Mainz, Germany. | Health Technology |
ImVisioN GmbH
ImVisioN GmbH Miscellaneous Commercial ServicesCommercial Services ImVisioN GmbH provides research in intralymphatic immunotherapy. It is a biotechnology company which specializes the use of intralymphatic immunotherapy to develop treatments for major allergies. Its product, IVN201, is a MAT immunotherapeutic that targets cat dander allergy, a common allergy inadequately addressed by available therapeutic interventions. The company was founded in 2005 and is headquartered in Hanover, Germany. | Commercial Services |
| Biovision AG | |
Pantec Biosolutions AG
 Pantec Biosolutions AG Drugstore ChainsRetail Trade Pantec Biosolutions AG provides laser microporation based transdermal drug delivery services. Its technology can be used for transdermal delivery, intradermal delivary, epidermal delivery, infertility patches, and aesthetic dermatology. The company was founded by Christof Böhler, Herbert Zech, Reinhard Braun, Werner Braun, and Thomas Bragagna in 2006 and is headquartered in Ruggell, Liechtenstein. | Retail Trade |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
| Center for Molecular Medicine (Sweden) | |
Helix Polska Sp zoo
 Helix Polska Sp zoo Pharmaceuticals: MajorHealth Technology Helix Polska Sp zoo develops therapeutic products. The company is based in Warsaw, Poland. | Health Technology |
| Tcer AB | |
Inprother ApS
Inprother ApS BiotechnologyHealth Technology Inprother ApS is a biotechnology company based in Copenhagen, Denmark. The Danish company aims to develop novel immunotherapies that target the human endogenous retroviruses (HERVs) as tumor-specific antigens. The company is funded by the Novo Nordisk Bioinnovation Institute and by grants from the Danish Innovation Fund and Eurostars. Inprother has put in place a world-class scientific team and created an emerging product development pipeline, including a leading program targeted to enter clinics in 2024. Inprother's approach is based on the research of founder and CTO, Dr. Peter Holst, and CTO, Dr. Anne-Marie Andersson. The company was founded in 2011 by Peter Johannes Holst. Jordi Naval has been the CEO of the company since 2021. | Health Technology |
